deCODE Genetics (Reykjavik, Iceland) has launched deCODE PrCa, a reference laboratory test for common, single-nucelotide polymorphisms (SNPs) in the human genome that the company has associated with increased risk of prostate cancer. Performed exclusively by deCode’s CLIA-certified reference lab, the test is priced at $500, which includes sample shipping costs. At this time, the test’s results are applicable only to white European males since research data are not currently available for other ethnicities for all the variants.

For more information on this newly launched test and the research behind it, see the March issue of Diagnostic Testing and Technology Report.